Phthalate metabolites Mono- (2-ethylhexyl) phthalate(MEHP) and Phthalic Acid Monobenzyl Ester (MBZP) are widely present in the environment, can interfere with the endocrine system and accumulate in human tissues, and are …
In recent years, there has been a surge of interest in alternative and natural techniques for preventing and treating gynecological disorders. Numerous studies have focused on exploring treatments that have …
Gynecologic postoperative adhesions (GPOA) remain an under-appreciated source of morbidity despite advances in minimally invasive surgery. Adhesions forming after myomectomy, extensive endometriosis excision, repeat caesarean section, or hysteroscopic adhesiolysis develop …
Endometrial regeneration is a cornerstone of reproductive health, with the extracellular matrix (ECM) playing a pivotal role in tissue repair, regeneration, and fertility restoration. Dysregulated ECM remodeling is at the …
Neuropeptide S (NPS) is a potent agonist for the GPCR receptor NPSR1, implicated in various physiological and pathological processes, including inflammation. NPSR1 gene polymorphisms have been linked to asthma, inflammatory …
Infective endocarditis (IE) following transcatheter atrial septal defect (ASD) device closure is a rare but life-threatening complication. We report a case of a 41-year-old woman who developed device-related IE five …
Endometriosis is a disease characterized by the presence of endometrial glands and stroma outside of the uterine corpus, often clinically presenting with pain and/or infertility. Ectopic lesions exhibit features characteristic …
To investigate the effects of microplastics (MPs) on the human endometrium in vitro.
The fibrosis mechanism in endometriosis is not elucidated. We investigated the role of eosinophil in fibrosis of endometriosis. The endometriotic stromal cells (ESCs) and endometrial epithelial cells (EECs) were subjected …
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …